Vaccine preparation containing fatty acid as a constituent
View Patent ↗The present invention provides an adjuvant that is a hydroxy unsaturated fatty acid or a derivative thereof, as well as a vaccine preparation containing the adjuvant as a constituent. For example, a vaccine shows sufficient activity to enhance the immunity when a hydroxy unsaturated fatty acid having the following structure is administered:
1. An adjuvant consisting of (i) 9,12,13-trihydroxy-10E-octadecenoic acid or a derivative thereof represented by any one of the formulae (I) or (III);
wherein R 1 is a hydroxyl group, or an oxygen, sulfur, or nitrogen atom substituted with one or two alkyl or aryl groups; and R 2 , R 3 , and R 4 may be identical or different and each represents hydrogen, an alkyl group, or an acyl group; or
wherein R 1 is a hydroxyl group, or an oxygen, sulfur, or nitrogen atom substituted with one or two alkyl or aryl groups; and R 2 , R 3 , and R 4 may be identical or different and each represents hydrogen, an alkyl group, or an acyl group, and (ii) a pharmaceutically acceptable carrier.
2. A vaccine preparation consisting of an antigen constituent and the adjuvant of claim 1 .
3. The vaccine preparation of claim 2 , wherein the adjuvant in the vaccine preparation is orally or transdermally administered independently of an antigen constituent.
4. The vaccine preparation of claim 2 , wherein the antigen constituent in the vaccine preparation is inoculated intranasally, subcutaneously, orally, transdermally, intramuscularly, or through mucosa by the other route.
5. The vaccine preparation of claim 2 , wherein the antigen constituent is one or more antigens from pathogenic microorganisms selected from the group consisting of influenza virus, rotavirus, measles virus, rubella virus, mumps virus, AIDS virus, Bordetella pertussis , diphtheria bacillus, Helicobacter pylori , enterohaemorrhagic Escherichia coli (EHEC)), Chlamydia, Mycoplasma , Malaria Plasmodium , coccidium and schistosome.
6. A method for administering the vaccine preparation of claim 2 , wherein the method comprises orally or transdermally administering the adjuvant in the vaccine preparation independently of the antigen constituent, wherein the adjuvant is administered concurrently with the antigen constituent.
7. A method for administering the vaccine preparation of claim 2 , wherein the antigen constituent is inoculated intranasally, subcutaneously, orally, transdermally, intramuscularly, or through mucosa by the other route, wherein the adjuvant is administered concurrently with the antigen constituent.
8. An adjuvant consisting of (i) 9,12,13-trihydroxy-10E-octadecenoic acid or a derivative thereof represented by any one of the formulae (I) or (III);
wherein R 1 is a hydroxyl group, or an oxygen, sulfur, or nitrogen atom substituted with one or two alkyl or aryl groups; and R 2 , R 3 , and R 4 may be identical or different and each represents hydrogen, an alkyl group, or an acyl group; or
wherein R 1 is a hydroxyl group, or an oxygen, sulfur, or nitrogen atom substituted with one or two alkyl or aryl groups; and R 2 , R 3 , and R 4 may be identical or different and each represents hydrogen, an alkyl group, or an acyl group, and (ii) a pharmaceutically acceptable carrier, wherein contaminants unnecessary for vaccination are not included.
9. The vaccine preparation of claim 2 , wherein contaminants unnecessary for vaccination are not included.